Bacterial Lysates on Respiratory Tract Microecology and Evaluation of the Efficacy of Prevention and Treatment of VAP
- Conditions
- Ventilators, Mechanical
- Interventions
- Drug: Bacterial LysatesOther: normal saline
- Registration Number
- NCT05270018
- Lead Sponsor
- Sheng Wang MD PhD
- Brief Summary
The purpose of this study is to assess the effect of bacterial lysates on respiratory tract microecology in patients with mechanical ventilation and the efficacy of prevention and treatment of ventilator associated pneumonia.
- Detailed Description
After being informed about the study and potential risks, all patients giving written informed consent will undergo a one-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to Bacterial Lysates( 14mg, once a day) or placebo(once a day).
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Patients admitted to ICU for mechanical ventilation
- The expected mechanical ventilation time is more than 72h
- Sign the informed consent form when conscious and voluntary, and complete the questionnaire survey and follow-up as required; If it is unable to sign the informed consent form and complete the questionnaire survey and follow-up, the legal representative or guardian can act on behalf of it.
- Ventilator associated pneumonia is known and confirmed
- Pregnant or lactating female
- Allergic to the active ingredients of bacterial lysates or any excipients listed in the ingredients
- Patients with autoimmune diseases
- Patients with acute intestinal infection
- Patients participating in other clinical studies at the same time
- Patients considered unsuitable by other researchers to participate in this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bacterial Lysate group Bacterial Lysates Oral / gastric administration of bacterial lysate once a day on an empty stomach, 14.0mg each time for at least 5 days Control group normal saline Oral / gastric administration of normal saline once a day, 14.0ml each time
- Primary Outcome Measures
Name Time Method VAP incidence 2 weeks The incidence rate of ventilator associated pneumonia
- Secondary Outcome Measures
Name Time Method Assessment of human immune status one week Immune status Assessment of IgG, IgA, and IgM levels Quantifications of IgG, IgA, and IgM levels were determined by Immunological Turbidity Kits
drug resistant bacteria Incidence one week The incidence rate of drug resistant bacteria
Composition of respiratory bacteria one week probiotics and pathogens via NGS analysis
survival rate 28 days ICU in-hospital mortality and 28 day mortality
Trial Locations
- Locations (1)
Shanghai Tenth People's Hospital
🇨🇳Shanghai, Shanghai, China